The combination remodels the TME through enhancing the activation and recruitment of CD8+ T cells and reduces the tumor burden in the OC mouse model.381 Combining anti-PD-L1, anti-PD1, or anti-CTLA4 therapy with a DNMT inhibitor enhances the antitumor immune response of CD8+ T cells and promotes a type I interferon response; clinical trials combining methyltransferase inhibitors and ICIs have begun.341,382–384 Utilizing hypomethylating drugs to revitalize CD8+ T cells prior to immune checkpoint therapy could be a useful strategy. Here, CD8A is linked to neoplasm.